1039399-17-1 Usage
General Description
PF-03654746, also known as 4-Methylbenzenesulfonate (1:1), is a chemical compound that belongs to the family of benzenesulfonates. It is commonly used in the pharmaceutical industry as a research chemical for drug discovery and development. PF-03654746 has been studied for its potential therapeutic applications, particularly in the treatment of cardiovascular and metabolic disorders. As a 4-Methylbenzenesulfonate, it has demonstrated promising pharmacological properties, including anti-inflammatory and anti-oxidative effects. Its chemical structure and properties make it a valuable tool for researchers and scientists in the pursuit of new drug candidates and therapeutic interventions. Additionally, it has shown potential as a building block for the synthesis of novel chemical compounds with diverse biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 1039399-17-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,9,3,9 and 9 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1039399-17:
(9*1)+(8*0)+(7*3)+(6*9)+(5*3)+(4*9)+(3*9)+(2*1)+(1*7)=171
171 % 10 = 1
So 1039399-17-1 is a valid CAS Registry Number.
1039399-17-1Relevant articles and documents
Discovery of two clinical histamine H3 receptor antagonists: Trans - N -ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl] cyclobutanecarboxamide (PF-03654746) and trans -3-fluoro-3-[3-fluoro-4- (pyrrolidin-1-ylmethyl)phenyl]- N -(2-methy
Wager, Travis T.,Pettersen, Betty A.,Schmidt, Anne W.,Spracklin, Douglas K.,Mente, Scot,Butler, Todd W.,Howard, Harry,Lettiere, Daniel J.,Rubitski, David M.,Wong, Diane F.,Nedza, Frank M.,Nelson, Frederick R.,Rollema, Hans,Raggon, Jeffrey W.,Aubrecht, Jiri,Freeman, Jody K.,Marcek, John M.,Cianfrogna, Julie,Cook, Karen W.,James, Larry C.,Chatman, Linda A.,Iredale, Philip A.,Banker, Michael J.,Homiski, Michael L.,Munzner, Jennifer B.,Chandrasekaran, Rama Y.
, p. 7602 - 7620 (2012/01/05)
The discovery of two histamine H3 antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success i
